Enlitic secures A$15M placement to fund AI imaging scale-up

What's the deal? Enlitic (ASX:ENL) has secured binding commitments for a conditional placement to raise about A$15 million before costs. The medical imaging software company will use the funds to sustain operations through to cashflow break-even and expand enterprise sales.

Why now? The raise follows a two-day trading halt requested on July 1, pending the outcome of the equity offer. Trading resumed with the stock up 20% to $0.006 on the Australian Securities Exchange.

What's the endgame? Enlitic builds software that uses artificial intelligence to manage medical imaging data. The placement will primarily fund the commercial scale-up of those products, which the company expects to provide an operational runway of over 12 months.

The transaction also includes a proposed 10:1 share consolidation and a security purchase plan targeting up to about A$1 million. "This capital raising represents a pivotal moment for Enlitic," said chief executive officer Michael Sistenich.

What could go wrong? This is a capital restructure rather than a category-defining round. Enlitic previously raised $15 million in a Series B led by MarubeniDealroom has a profile for this one. Try Dealroom →, so the story reads as more incremental than transformative absent a major regulatory milestone.

The signal: The raise follows commercial progress in 2026, including data migration agreements with hospital groups such as Parkland Health and Penn Medicine. That ties the funding to clinical deployment — the measure that matters most for AI imaging companies moving from development into the market.

Read more: Grafa

Image credit: National Institutes of Health (NIH)